ENDPOINTS

Bristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drug

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-develop and ...

Jun 2, 2025 - 13:14
 0
Bristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drug
BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-develop and ...
Read More

Tags:

Previous Article

Don't miss the half-lit first quarter moon rise tonight: Here's what to look for

Next Article

‘We need new numbers’: Comedian David Cross cracks jokes to spread climate crisi...

Related Posts

Biohaven stock sinks on three-month delay for neuro drug FDA approval decision

Biohaven stock sinks on three-month delay for neuro dru...

May 15, 2025  0

Pharma companies consider first sale rule to ease tariff impact

Pharma companies consider first sale rule to ease tarif...

May 22, 2025  0

Trump unofficially taps CMS chief Oz to spearhead 'most favored nation' talks

Trump unofficially taps CMS chief Oz to spearhead 'most...

May 23, 2025  0